Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2
Authors:
- Andrew BlauveltABAndrew Blauvelt
- Kenneth B. GordonKGKenneth B. Gordon
- Richard G. LangleyRLRichard G. Langley
- Patrick J. BraniganPBPatrick J. Branigan
- Yanqing ChenYCYanqing Chen
- Megan MillerMMMegan Miller
- Chenglong HanCHChenglong Han
- Steven FakharzadehSFSteven Fakharzadeh
- Ernesto J. Muñoz-ElíasEMErnesto J. Muñoz-Elías
- April W. ArmstrongAAApril W. Armstrong
Open Access
- 25 June 2024
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (12) , 2816-2819.e2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Mapping DNA interaction landscapes in psoriasis susceptibility loci highlights KLF4 as a target gene in 9q31BMC Biology, 2020
- Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United StatesJournal of the American Academy of Dermatology, 2019
- Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 StudiesAmerican Journal of Clinical Dermatology, 2018
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trialJournal of the American Academy of Dermatology, 2017
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trialJournal of the American Academy of Dermatology, 2017
- Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diaryJournal of Dermatological Treatment, 2015
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011PLOS ONE, 2012
- Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of DiseasePLOS ONE, 2012
- Resolved Psoriasis Lesions Retain Expression of a Subset of Disease-Related GenesJournal of Investigative Dermatology, 2011